BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 03/06/2004

Agency Emergency Processing Under OMB Review; Experimental Study of Petitioned Health Claims on Glucosamine and Chondroitin Sulfate

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for emergency processing under the Paperwork Reduction Act of 1995 (the PRA). The proposed collection of information is in response to a petition for health claims for glucosamine and chondroitin sulfate. The study examines various petitioned health claims about the effect of glucosamine and chondroitin sulfate on osteoarthritis. The goal of the study is to determine if certain claims about glucosamine and/or chondroitin (the "product") and the reduction of risk of specific outcomes related to osteoarthritis, namely joint degradation and cartilage deterioration, create misperceptions on the part of consumers about the intended use of the product.

Source: Federal Register — Food and Drug AdministrationOpen original release →